No Data
No Data
H.C. Wainwright Maintains Atara Biotherapeutics(ATRA.US) With Hold Rating
Atara Biotherapeutics: Hold Rating Maintained Amid Financial Shortfalls and Regulatory Uncertainties
Atara Biotherapeutics (ATRA) Gets a Hold From Stifel Nicolaus
Mizuho Securities Upgrades Atara Biotherapeutics(ATRA.US) to Buy Rating, Cuts Target Price to $18
Express News | Atara Biotherapeutics Inc : Mizuho Raises to Outperform From Neutral; Cuts Target Price to $18 From $25
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Just Reported Earnings, And Analysts Cut Their Target Price
Trytosaveabit : I can’t believe with the monster revenue increase this isn’t moving! Over 2000% increase
Jaguar8 OP Trytosaveabit : Maybe let’s wait tomorrow. Maybe they are too happy with their GNLN earnings![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
Trytosaveabit Jaguar8 OP : Hehehe! Yeah you’re right.
Joo Mey : hye dude..what do you think about ffie?
Jaguar8 OP Joo Mey : I try to avoid it. Super high ritual for dilution. Negative cash flow